Skip to content

A clinical trial on the feasibility and safety of transumbilical single-incision laparoscopic gastrectomy for gastric cancer combined with enhanced recovery after surgery

A clinical trial on the feasibility and safety of transumbilical single-incision laparoscopic gastrectomy for gastric cancer combined with enhanced recovery after surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015109
Enrollment
Unknown
Registered
2018-03-07
Start date
2018-03-26
Completion date
Unknown
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

A:Single Incision operation
B:Single incision operation combined with ERAS
C:five port operation

Sponsors

Department of General Hospital, Second affiliated hospital, Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 75 years, male and female; (2) patients with gastric cancerdiagnosed by cytological or histological examination, requires surgical treatment; (3) ECOG score0/1 preoperation; (4) ASA soore I-III preoperation; (5) Informed consent was signed as voluntarily before study; (6) Patients with no other malignant tumors at the same time; without having surgery history of gastric resection.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors at the same time; 2. patients having surgery history of gastric resection; 3. patients having a history of mediastinal surgery or vast peritoneal adhesion; 4. patients with heart thromboembolism at the same time; 5. People with psychological, mental or nervous system diseases; 6. Cachexia, severe malnutrition patients; 7. Patients with history of recent recurrence of gastric ulcer, stomach bleeding and other severe basic diseases; 8. Patients with blood coagulation dysfunction, HIV antibody positive, or surgical contraindications such as clinically poorly controlled serious infection; 9. The subjects with other associated disease (such as liver and renal dysplasia, etc.) or drug combination, which could influence the study results recognized by the researchers; 10. Patients participating in another clinical study; 11. Patients with surgical instruments material allergy, or allergic constitution; 12. The subjects are not judged by investigator to participate in this Clinical trial.

Design outcomes

Primary

MeasureTime frame
Number of intraoperative lymph node dissection;Conversion rate of single incision laparoscopic surgery;

Secondary

MeasureTime frame
the first flatus post operation;the first defecation time post operation;the first time to eat forming food post operation;independent ambulation time after operation;post operation hospitalizaition time;post operation pain score;umbilical incision length;operation time;inflamatory biomarker;

Countries

China

Contacts

Public ContactWeidong Xiao

Second affiliated hospital, Army Medical University

weidong.xiao@126.com+86 17783879798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026